Studies conducted in adults and children suggest that insulin resistance and glucose alteration are more frequent in GH treated subjects with risk factors like age, obesity, an adverse metabolic profile before therapy, syndromes or history of tumors [16]. The gene discussed is GH1; the disease is obesity due to melanocortin 4 receptor deficiency.